Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Coyle

Showing results (581-590 of 589) with videos related to

Pageof 59
Sort By:
You have reached the last page of results.This site can display upto 589 results.
Nature Neuroscience|October 24, 2020
Activated microglia cause metabolic disruptions in developmental cortical interneurons that persist in interneurons from individuals with schizophreniaGun-Hoo Park, Haneul Noh, Zhicheng Shao, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 4, 2021
Dopaminergic neuromodulation of prefrontal cortex activity requires the NMDA receptor coagonist d-serineGlenn Dallérac, Xia Li, Pierre Lecouflet, et al.
Molecular Psychiatry|August 29, 2024
An increased copy number of glycine decarboxylase (GLDC) associated with psychosis reduces extracellular glycine and impairs NMDA receptor functionMaltesh Kambali, Yan Li, Petr Unichenko, et al.
Neurology|May 9, 2008
Cell-based interventions for neurologic conditions: ethical challenges for early human trialsD J H Mathews, J Sugarman, H Bok, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|August 30, 2008
The role of animal models in evaluating reasonable safety and efficacy for human trials of cell-based interventions for neurologic conditionsAlan Regenberg, Debra J H Mathews, David M Blass, et al.
The American Journal of Bioethics : AJOB|April 28, 2009
Unintended changes in cognition, mood, and behavior arising from cell-based interventions for neurological conditions: ethical challengesP S Duggan, A W Siegel, D M Blass, et al.
Biological Psychiatry|July 8, 2019
Targeted Treatment of Individuals With Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase GeneJ Alexander Bodkin, Michael J Coleman, Laura J Godfrey, et al.
Nature Neuroscience|January 22, 2019
Dysregulated protocadherin-pathway activity as an intrinsic defect in induced pluripotent stem cell-derived cortical interneurons from subjects with schizophreniaZhicheng Shao, Haneul Noh, Woong Bin Kim, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 14, 2017
Probing the lithium-response pathway in hiPSCs implicates the phosphoregulatory set-point for a cytoskeletal modulator in bipolar pathogenesisBrian T D Tobe, Andrew M Crain, Alicia M Winquist, et al.
Pageof 59

Showing results (581-590 of 589) with videos related to

Sort By:
Pageof 59
You have reached the last page of results.This site can display upto 589 results.
Nature Neuroscience|October 24, 2020
Activated microglia cause metabolic disruptions in developmental cortical interneurons that persist in interneurons from individuals with schizophreniaGun-Hoo Park, Haneul Noh, Zhicheng Shao, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 4, 2021
Dopaminergic neuromodulation of prefrontal cortex activity requires the NMDA receptor coagonist d-serineGlenn Dallérac, Xia Li, Pierre Lecouflet, et al.
Molecular Psychiatry|August 29, 2024
An increased copy number of glycine decarboxylase (GLDC) associated with psychosis reduces extracellular glycine and impairs NMDA receptor functionMaltesh Kambali, Yan Li, Petr Unichenko, et al.
Neurology|May 9, 2008
Cell-based interventions for neurologic conditions: ethical challenges for early human trialsD J H Mathews, J Sugarman, H Bok, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|August 30, 2008
The role of animal models in evaluating reasonable safety and efficacy for human trials of cell-based interventions for neurologic conditionsAlan Regenberg, Debra J H Mathews, David M Blass, et al.
The American Journal of Bioethics : AJOB|April 28, 2009
Unintended changes in cognition, mood, and behavior arising from cell-based interventions for neurological conditions: ethical challengesP S Duggan, A W Siegel, D M Blass, et al.
Biological Psychiatry|July 8, 2019
Targeted Treatment of Individuals With Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase GeneJ Alexander Bodkin, Michael J Coleman, Laura J Godfrey, et al.
Nature Neuroscience|January 22, 2019
Dysregulated protocadherin-pathway activity as an intrinsic defect in induced pluripotent stem cell-derived cortical interneurons from subjects with schizophreniaZhicheng Shao, Haneul Noh, Woong Bin Kim, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 14, 2017
Probing the lithium-response pathway in hiPSCs implicates the phosphoregulatory set-point for a cytoskeletal modulator in bipolar pathogenesisBrian T D Tobe, Andrew M Crain, Alicia M Winquist, et al.
Pageof 59